What's new

In the northern region of China, there is currently a large-scale outbreak of infections, including mycoplasma pneumonia, influenza, and COVID-19. "Mycoplasma pneumonia" is particularly prevalent, and it is an atypical pathogen causing pneumonia.

In southern Taiwan, there is a significant outbreak of Dengue fever, with the number of infections surpassing thousands of cases this year, reaching a new high for the same period in the past ten years according to statistics from the Centers for Disease Control (CDC). In order to overcome the challenges in treating De

GeneOnline had an exclusive interview with Taiwan’s 元樟生技 AMS BioteQ at the #2023_Medical_Japan_Tokyo.

Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the spotlight.

AMS BioteQ: Pioneering Innovation in Antibiotics and Advanced Dressings
Since its establishment in 2018, AMS BioteQ, headquartered in Taiwan, has dedicated itself to the development of cutting-edge antibiotics and antimicrobial dressings.

Despite the ongoing prevalence of dengue fever in Taiwan, the primary method of epidemic prevention in our country still relies on traditional mosquito spray.

AMS BioteQ collaborates with Professor Sheng-Fan Wang, Director of the Center for Tropical Medicine and Infectious Diseases Research at Kaohsiung Medical University

As the prices of eggs and chicken soar, avian influenza is posing a significant challenge to human society. The virus, which used to be limited to birds, has recently been reported to infect humans.

We sincerely appreciate everyone’s long-term support and care for AMS BioteQ. On April 30, 2022, our company officially moved into the Kaohsiung Shi-Wei Financial Center. With a design layout brimming with modernity, we showcase our innovation and expertise, enhancing our overall service capability.

Another Breakthrough in Epidemic Prevention! The Team at Kaohsiung Medical University Has Developed a COVID-19 Antibody Testing Platform for Precise Assessment of Antibody Efficacy

Yuanta Securities has been appointed as the recommended securities firm for AMS BioteQ Emerging Stock Board since February 25, 2022!

AMS BioteQ Chairman, Dr. Yi-Ju Tsai (center), and the team are actively conducting research to develop potential new drugs and address the unmet topical medication market.
Antibiotic-Resistant Superbug – one of the greatest threats to human health.